Ageism Leaves Older Patients Out Of Important Clinical Trials For COVID-19, Says Harvard Researcher

Download Audio

The race to find new treatments for the coronavirus is heating up throughout the country, including here in Massachusetts, as vaccines and treatments progress into human trials.

But a recent review led by Harvard Medical School researchers shows elderly people are routinely excluded from COVID-19 treatment trials, even as 80% of COVID-related deaths occur in people over age 65.

Dr. Sharon Inouye, a geriatrician with Harvard Medical School and Hebrew SeniorLife who led that study, joined WBUR's Morning Edition to talk about how ageism is affecting COVID-19 treatments.

This article was originally published on June 25, 2020.


Headshot of Bob Oakes

Bob Oakes Senior Correspondent
Bob Oakes was a senior correspondent in the WBUR newsroom, a role he took on in 2021 after nearly three decades hosting WBUR's Morning Edition.


Headshot of Khari Thompson

Khari Thompson Producer, Radio Boston
Khari Thompson is a producer for Radio Boston.



More from WBUR

Listen Live